A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00583154
Recruitment Status : Completed
First Posted : December 31, 2007
Last Update Posted : September 28, 2009
Information provided by:
Braintree Laboratories

Brief Summary:
To compare the safety and efficacy of BLI-801 administered at 4 dose levels in constipated adults.

Condition or disease Intervention/treatment Phase
Constipation Drug: BLI-801 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults
Study Start Date : October 2007
Actual Primary Completion Date : January 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
BLI-801 Dose 1
Drug: BLI-801
Dose 1
Experimental: 2
BLI-801 Dose 2
Drug: BLI-801
Dose 2
Experimental: 3
BLI-801 Dose 3
Drug: BLI-801
Dose 3
Experimental: 4
BLI-801 Dose 4
Drug: BLI-801
Dose 4

Primary Outcome Measures :
  1. Bowel Movement Count [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects at least 18 years of age
  • Constipated according to ROME I criteria
  • Otherwise in good health, as determined by physical exam and medical history
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse)
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
  • Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments for the duration of the study
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study
  • Subjects of childbearing potential who refuse a pregnancy test
  • Subjects who are allergic to any BLI-801 component.
  • Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00583154

United States, California
Anaheim, California, United States
United States, Rhode Island
Cranston, Rhode Island, United States
Cumberland, Rhode Island, United States
Sponsors and Collaborators
Braintree Laboratories
Study Director: John McGowan Braintree Laboratories, Inc.

Responsible Party: John McGowan, Clinical Operations Manager, Braintree Laboratories, Inc. Identifier: NCT00583154     History of Changes
Other Study ID Numbers: BLI-801-101
First Posted: December 31, 2007    Key Record Dates
Last Update Posted: September 28, 2009
Last Verified: September 2009

Keywords provided by Braintree Laboratories:

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Agents